In the race to be the frontrunner in the CAR-T therapy field, the two companies currently in the lead position look to be mirroring each other’s progress.
Swiss pharma giant Novartis (NOVN: VX) might have won the race for US approval with Kymriah (tisagenlecleucel), but the nod for Gilead's Sciences’ (Nasdaq: GILD) Yescarta (axicabtagene ciloleucel), which the company acquired via its $11.9-billion purchase of Kite Pharma, followed weeks later.
So on the weekend that Novartis presented encouraging follow-up data on Kymriah, it was no surprise to see the US biotech company putting forward an updated analysis on Yescarta (axicabtagene ciloleucel).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze